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Abstract 
Much of the justification for environmental rulemaking rests on estimates of the benefits to 
society of reduced mortality rates.   Yet the literature providing estimates of the willingness to pay  
(WTP) for mortality risk reductions measures the value that healthy, prime-aged adults place on reducing 
their risk of dying, whereas the majority of statistical lives saved by environmental programs, according 
to epidemiological studies, appear to be the lives of older people and people with chronically impaired 
health. 
This paper provides an empirical assessment of the effects of age and baseline health on WTP for 
mortality risk reductions by reporting the results of two contingent valuation surveys designed to test the 
above hypotheses. One survey was administered in-person to residents of Hamilton, Ontario, and the 
other to a nationally representative sample of U.S. residents using the Internet.  Both surveys elicited 
respondents’ WTP for reductions in mortality risk of different magnitudes. Respondents were limited to 
persons aged 40 years and older, including those older than 60, to examine the impact of age on WTP. 
Extensive information was collected about each respondent’s health status to see whether it systematically 
influenced WTP.  
Our results provide weak support for the notion that WTP declines with age, but only after age 
70. Specifically, in our Canadian sample, WTP declines by about 30% after age 70 compared with WTP 
at younger ages. There is no such statistically significant decline, however, in the U.S. sample. We 
similarly find no support for the idea that people who have cancer or chronic heart or lung disease are 
willing to pay less to reduce their risk of dying than people without these illnesses. If anything, people 
with these illnesses are willing to pay more. 
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Does the Value of a Statistical Life Vary with Age and Health Status? 
Evidence from the United States and Canada 
Anna Alberini, Maureen Cropper, Alan Krupnick, and Nathalie B. Simon∗ 
I. Introduction 
Much of the justification for environmental rulemaking rests on estimates of the benefits 
to society of reduced mortality rates. Reductions in risk of death are arguably the most important 
benefit underlying drinking water regulations, as well as regulations that govern air pollution and 
the disposal of hazardous waste. In two recent analyses of the benefits of the U.S. Clean Air Act 
(U.S. EPA 1997; U.S. EPA 1999), more than 80% of monetized benefits were attributed to 
reductions in premature mortality. Similarly, a high proportion of the monetized benefits of 
Canadian air quality regulations are attributable to reductions in premature mortality (Canada-
Wide Standards Development Committee for PM and Ozone 1999). 
In studies conducted in the United States and Canada, estimates of individuals’ 
willingness to pay (WTP) for mortality risk reductions and the implied value of a statistical life 
(VSL) come from revealed preference studies, primarily studies of compensating wage 
differentials in the labor market, as well as stated preference (contingent valuation) studies.1 The 
use of figures from these studies to value the lives saved by environmental programs is, however, 
problematic. Both types of studies have focused on measuring the value that healthy, prime-aged 
adults place on reducing their risk of dying, whereas the majority of statistical lives saved by 
environmental programs, according to epidemiological studies, appear to be the lives of older 
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1 The Environmental Protection Agency’s official VSL is based on 26 studies, of which 21 are hedonic labor market 
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people and people with chronically impaired health (Pope et al. 1995; Schwartz 1991; Schwartz 
1993).  
There are two reasons why older persons are likely to benefit disproportionately from 
reductions in pollution. First, epidemiological studies typically assume that the effects of a 
change in exposure are proportional to baseline mortality (Pope et al. 1995; Morales et al. 2000). 
Since persons over 65 account for three-quarters of all deaths in the United States and Canada, a 
larger proportion of statistical lives will be saved among the old than among the young. Second, 
some epidemiological studies have found larger changes in mortality rates for people over 64 
than for younger people (Schwartz 1991, 1993). Epidemiological studies also suggest that 
persons with chronic heart or lung conditions are likely to benefit disproportionately from 
improvements in air quality (Schwartz 1991; Schwartz and Dockery 1992; Pope et al. 1995). 
It has been conjectured that older people should be willing to pay less for a reduction in 
their risk of dying than younger people on the grounds that they have fewer expected life years 
remaining. Indeed, some economists have argued that the VSL should be converted to a value 
per statistical life year (VSLY), and that lives saved should be valued by multiplying remaining 
life expectancy by the VSLY (Moore and Viscusi 1988). This procedure assumes, implicitly, that 
each year of life is equally valuable, and that the VSL is strictly proportional to remaining life 
expectancy. Whether this approach is consistent with welfare economics, however, depends on 
how, empirically, WTP for a reduction in risk of death varies with age.  
It has also been argued that people in ill health should be willing to pay less for a 
reduction in their risk of dying because their utility from an additional year of life is lower than 
that of healthy people. In the literature on quality-adjusted life years (QALYs), saving the life of 
a person with chronic bronchitis is less valuable than saving the life of a person in good health 
(Gold et al. 1996). This has been used as an argument for assigning a lower VSL to beneficiaries 
of air pollution control programs than the value the Environmental Protection Agency (EPA) 
currently uses (EOP Group, Inc. 1997). There is no empirical evidence, however, showing that 
people with chronic heart and lung disease would pay less than healthier individuals to reduce 
their risk of dying.  
This paper provides an empirical assessment of the effects of age and baseline health on 
WTP for mortality risk reductions by reporting the results of two contingent valuation surveys 
designed to test the above hypotheses. One survey was administered to residents of Hamilton, 
Ontario, and the other to a nationally representative sample of U.S. residents. Both surveys 
elicited respondents’ WTP for reductions in mortality risk of different magnitudes. Respondents Resources for the Future  Alberini et al. 
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were limited to persons aged 40 years and older, including those older than 60, to examine the 
impact of age on WTP. Extensive information was collected about each respondent’s health 
status to see whether it systematically influenced WTP.  
Our results provide weak support for the notion that WTP declines with age, but only 
after age 70. Specifically, in our Canadian sample, WTP declines by about 30% after age 70 
compared with WTP at younger ages. There is no such statistically significant decline, however, 
in the U.S. sample. We similarly find no support for the idea that people who have cancer or 
chronic heart or lung disease are willing to pay less to reduce their risk of dying than people 
without these illnesses. If anything, people with these illnesses are willing to pay more. 
The remainder of this paper is organized as follows. Section II discusses how age and 
health status might influence WTP in the context of a life-cycle model of WTP for reductions in 
mortality risk. The survey instrument and its administration are discussed in section III. Section 
IV describes the characteristics of our samples and summarizes their responses to the 
questionnaire. Section V presents econometric models of WTP, and section VI concludes. 
II. How Should Age and Health Status Affect WTP for Mortality Risks? 
In this section we discuss how age and health status should influence WTP for a change 
in mortality risk, in the context of the life-cycle consumption model with uncertain lifetime 
(Yaari 1965). Several authors (Shepard and Zeckhauser 1982; Cropper and Sussman 1990) have 
used this model to derive an expression for an individual’s WTP for a reduction in his risk of 
death. We summarize these results here and discuss their implications for the effects of age and 
health status on WTP.  
In the life-cycle model, a person at the beginning of period j receives expected utility of  
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Vj is the present value of utility of consumption in each period, ut(Ct) , times the 
probability that the individual survives to that period, qj,t, discounted to the present at the 
subjective rate of time preference, ρ. Vj is maximized subject to initial wealth, Wj, and a budget 
constraint that reflects opportunities for borrowing and lending. The two cases usually 
considered are the case of actuarially fair annuities and the more realistic situation in which the 
individual can borrow and lend at the riskless rate r, but can never be a net borrower, Resources for the Future  Alberini et al. 
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The life-cycle model can be used to determine the amount of initial wealth that an 
individual would give up to reduce Dj, the probability that he dies during the current period. A 
reduction in Dj will increase the probability that the person survives to all future periods since, 
by definition, qj,t is the product of the probabilities that the individual does not die in all periods 
from j to t-1, 
(3)qj,t = (1-Dj)(1-Dj+1) . . . . (1-Dt-1).  
 
The rate of substitution between Dj and Wj corresponds to the value of a statistical life for 
a person of age j, VSLj,  
(4)VSLj = (∂Vj/∂Dj)/( ∂Vj/∂Wj) = dWj/dDj .  
The amount an individual is willing to pay for the change in Dj is, in turn, the product of 
the VSLj and the size of the risk reduction,  
(5) WTPj = (VSLj)dDj .   
If actuarially fair annuities are not available but the individual can borrow and lend at the 
rate r, VSLj may be written as the product of the reciprocal of the probability that the individual 
survives the current period, (1-Dj)
-1, times the present value of expected utility of consumption 
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How should the VSL change with age j? The first term in (6), (1-Dj)
-1, unambiguously 
increases with age: As people age, their probability of surviving the current period falls, and for 
this reason, their WTP to reduce their risk of death should increase. How the present value of 
expected utility of consumption—the remainder of the equation—changes with age is 
ambiguous. If utility of consumption ut(Ct) were constant over time, then the present value of 
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hypothesis that WTP for mortality risk reductions should fall with age. In general, however, 
ut(Ct) is not constant, and the impact of age on WTP is therefore ambiguous. 
If health status at age j, Hj, is treated as exogenous, it can easily be incorporated in 
equation (6).2 If lower values of Hj signify poorer health, then the first term on the right-hand 
side of (6) will be higher the lower is Hj. Persons in poorer health presumably have smaller 
chances of surviving the current period and, for that reason, should be willing to pay more to 
reduce Dj. The impact of current health on the rest of the equation is, however, ambiguous. Even 
if discounted remaining life expectancy is lower for people with lower current health status, one 
can say little about their time pattern of consumption, or about the way in which health affects 
the marginal utility of consumption.   
The implications of this section are that little can, in general, be said about the impact of 
current age (j) or current health status (Hj) on the value of mortality risk reductions. Older people 
and people in poorer health should have higher WTPs because their chance of surviving the 
current period is lower than that of younger, healthier individuals. Even though discounted 
remaining life expectancy should fall with age and current health status, it is discounted expected 
utility of consumption that matters in determining WTP, and the impact of age and health status 
on this term is ambiguous. The expression for the VSL and for WTP also suggests that it would 
be difficult empirically to estimate anything but a reduced-form relationship among WTP, age, 
and health status. 
 
III. The Surveys 
A. The Commodity Valued 
The goal of our surveys is to estimate individuals’ WTP for a reduction in their 
conditional probability of dying during the current period (Dj). Periods are treated as 10 years 
long.3 After being told the baseline risk of death over the next 10 years for someone of their race 
and gender, individuals are asked whether they would purchase a product (not covered by health 
                                                 
2 If health status were endogenous, one would have to examine the impact of a change in Dj on expenditures on 
health. 
3 In focus groups, individuals more readily accepted information about their risk of dying and changes in their risk 
of dying over a 10-year period than over shorter periods. Resources for the Future  Alberini et al. 
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insurance) that would reduce this risk by either 1 in 1,000 (1 in 10,000 annually) or 5 in 1,000 (5 
in 10,000 annually), at a stated price.4 Payment for the commodity is to be made annually, over 
10 years. 
Both the baseline risk of death and the risk reductions are communicated graphically. 
Baseline risk of death over the next 10 years is represented by coloring in red the appropriate 
number of squares on a white grid containing 1,000 squares. Reductions in risk of death are 
shown by turning the appropriate number of red squares to blue.  
B. The Structure of the Survey 
Our survey begins with a series of questions about the respondent’s health history and the 
health history of his family. This is followed by exercises that acquaint the respondent with the 
concept of risk and test his risk comprehension. Subjects are introduced to simple probability 
concepts using coin tosses and roulette wheels, working up to our standard risk communication 
device—a 1,000-square grid in which risks are represented using red squares. To test their 
comprehension, respondents are asked to compare grids for two hypothetical people (person A 
and person B) and to determine which of the two has the higher risk of death. They are also 
asked to select which person they would rather be. The baseline risk of death for a person of the 
respondent’s age and gender is then presented both numerically and graphically.  
It is sometimes argued that respondents in contingent valuation surveys find it difficult to 
report their WTP for a mortality risk reduction because they are not accustomed to trading 
income for reduced risks. To mitigate this problem, we first acquaint respondents with 
quantitative risk reductions resulting from medical tests and products that are likely to be 
familiar to the respondent (e.g., mammograms, colon cancer screening tests, medicine to reduce 
blood pressure). In doing so, we provide only qualitative cost information for each action or 
product (“inexpensive,” “moderate,” and “expensive”). 
This is followed by the WTP questions. Information about WTP is obtained through a 
combination of dichotomous choice payment questions with followups, and open-ended 
questions. Figure 1 shows the structure of each WTP question. Respondents are asked an initial 
                                                 
4 We chose a risk reduction of this order of magnitude because risk changes valued in labor market studies are 
typically of this size, and risk reductions of comparable size are often delivered by environmental programs (e.g., air 
pollution control).  Resources for the Future  Alberini et al. 
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dichotomous choice question: would they pay for the product at a price randomly chosen from 
one of four predetermined values? (See Table 1 for bid values.) Those respondents who 
answered yes were asked whether they would pay a higher price, and those who answered no 
were asked whether they would pay a lower price. A final, open-ended question was asked of 
those respondents who gave “yes-yes” or “no-no” responses. 
Each respondent was asked his WTP for two risk reductions. Respondents in Wave 1 of 
each survey were asked to value the 5-in-1,000 risk reduction first, whereas respondents in Wave 
2 were asked to value the 1-in-1,000 risk reduction first. After each question, respondents were 
asked to indicate their degree of certainty about the WTP responses on a scale from 1 to 7. 
Because WTP can be affected by the respondent’s understanding of risks and interpretation of 
the scenario, we included debriefing questions at the end of the questionnaire to identify 
respondents who had trouble comprehending the survey or who did not accept the risk reduction 
being valued. The survey ends with questions about the respondent’s income, followed by Short 
Form 36 (SF-36), a questionnaire commonly used in medical research to measure mental and 
physical health status (Ware et al. 1997). 
C. Administration of the Questionnaire 
The Canadian survey was self-administered using a computer by a sample of 930 
residents of Hamilton, Ontario. Subjects were recruited by telephone through random-digit 
dialing and asked to take the survey at a facility in downtown Hamilton.5 The survey took place 
over five months in spring 1999. 
The respondents in the U.S. survey were reached through a technology called Web-TV©, 
which involves attaching a special device (resembling a cable box) to a television. A remote 
control device or a keyboard enables the user to access the Internet, using the TV as a monitor. 
Knowledge Networks® recruited individuals to participate as panel members in exchange for the 
technology and free Internet access. The panel members were recruited by telephone using 
                                                 
5 Because of the need to travel to a centralized facility, response rates were low. Of 17,841 residential phone 
contacts, 8,260 were “cooperative,” but 4,917 households proved ineligible for age reasons. Among the 3,591 
eligible households, 455 declined to participate because of mobility problems and 1,079 refused, stating that the 
incentive payment (C$35) was insufficient. 1,545 persons agreed to participate in the survey, but in fact only 930 
(60%) kept their appointments. All persons who began the survey completed it. The response rate, calculated as the 
number of respondents successfully completing the study (930) divided by the number of eligible contacts (3,591), 
was thus 26%. Resources for the Future  Alberini et al. 
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random-digit dialing and were representative of the U.S. population in gender, age, race, and 
income. Panel members were randomly selected to complete surveys.6 Knowledge Networks® 
administered our survey to a selected sample of U.S. adults fitting our age profile in August 
2000. 1,800 persons were contacted to take the survey, and within two days 1,200 of them (our 
target sample) had completed the survey. 
IV. Sample Characteristics and Responses 
A. Characteristics of the Respondents 
The respondents in our Canadian and U.S. surveys were somewhat different, since they 
were sampled from different populations. In this section we describe our respondents, focusing 
on their age and health. Table 2 describes features of each sample other than health. It shows that 
both samples were well balanced in terms of gender, with each having slightly more women than 
men. Although respondents in the Canadian study were all Caucasian, the U.S. sample included 
blacks (11%) and Hispanics (8%).  
In part because of the differing racial compositions, the baseline risks reported to the 
respondents were different in the two studies. The average baseline risk was 123 in 1,000 for the 
Canadian sample, and 187 in 1,000 for the U.S. sample. African Americans, included in the U.S. 
sample, typically have higher baseline risks—except when very old—compared with Caucasians. 
The U.S. sample also included respondents over 75, whereas the Canadian sample did not. When 
these elderly respondents and African Americans are excluded from the U.S. sample, baseline 
risks decline substantially and are comparable to those for the Canadian sample.  
Average household incomes were similar in both studies, as were years of schooling (on 
average, about 13 years in both studies). The U.S. study recruited participants from areas that 
were classified as neither urban nor suburban (22%), but the Canadian study, by design, covered 
only residents of the urban and suburban area of Hamilton. 
                                                 
6 More information about Knowledge Networks is available from the company’s website: 
www.knowledgenetworks.com. Resources for the Future  Alberini et al. 
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B. Respondents’ Health 
We obtained a variety of information about respondents’ health. First, we asked 
respondents to rate their health as excellent, very good, good, fair or poor, compared with others 
the same age. We then asked them whether they had been diagnosed with various illnesses, 
including asthma, chronic bronchitis, emphysema, various heart ailments, cancer, high blood 
pressure, and stroke. We also inquired about time spent in the hospital. Finally, we administered 
all the questions from SF-36.  
Table 3 displays descriptive statistics for the health status of the respondents. Because 
participants in the Canadian study had to be well enough to travel to a central facility to complete 
the questionnaire, this sample was likely to be relatively healthy. By contrast, respondents in the 
U.S. study participated from their homes, allowing the inclusion of less healthy individuals and 
persons with impaired mobility. The difference in health status across the samples is borne out in 
the table. A slightly higher percentage of respondents in the Hamilton sample described 
themselves as having good or excellent health relative to others the same age (57.2%) compared 
with the U.S. sample (53.1%). Furthermore, the fractions of the sample with various types of 
chronic illness were slightly higher in the United States.7 Although 3.4% of the Hamilton 
respondents said they had been diagnosed with cancer (a figure in line with the area’s official 
health statistics), 11% of the U.S. sample reported having been diagnosed with cancer.   
C. Probability Comprehension and Acceptance of the Scenario 
Valuing mortality risk reductions through direct questioning techniques requires that 
subjects understand probabilities and accept the WTP scenarios presented to them. This section 
summarizes respondents’ comprehension of probabilities and reports the percentage of 
respondents who questioned the assumptions made in the survey. Respondents who failed our 
probability tests were dropped from the analysis. Responses to debriefing questions indicating 
                                                 
7 The questions on chronic illness were asked differently in the two studies. Canadian respondents were asked, in a 
single question, whether they had ever been diagnosed with one or more of the following illnesses: asthma, 
bronchitis, or emphysema. Respondents in the U.S. study, however, were asked whether they had ever been 
diagnosed with each of the following illnesses in four separate questions (i) asthma, (ii) chronic bronchitis, (iii) 
emphysema, or (iv) other respiratory illnesses. Similarly, the respondents in Hamilton were asked whether they had 
been diagnosed with heart disease, whereas the subjects in the U.S. study were asked four questions—whether they 
had ever been diagnosed with (i) angina pectoris, (ii) coronary heart disease, or (iii) other heart disease, and (iv) 
whether they had ever had a heart attack. Resources for the Future  Alberini et al. 
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that the respondent did not believe his baseline risk of death or had doubts about the 
effectiveness of the product were used to create dummy variables. In table A1, we show results 
from a test of whether people who questioned some aspect of the questionnaire had significantly 
different WTP from those who did not. 
To test their comprehension of probabilities, we asked respondents several questions 
using side-by-side grids of squares to convey the chances of dying for two people, person A and 
person B. The first question, the probability test question, asks which of the two people has the 
higher probability of dying. The second question, the probability choice question, asks which of 
the two people the respondent would rather be. If respondents answer the probability test 
question incorrectly, another explanation of the concept is provided and the respondent is asked a 
second probability test question. Should respondents indicate a preference for the person with the 
higher risk in the choice question, they are asked to confirm their selection following an 
additional explanation of the grids.  
Table 4 reports the results of the probability test and choice questions. The table shows 
that roughly 12% of the respondents answered the initial probability test incorrectly. However, 
following an explanation of the error, a much smaller portion provided an incorrect answer to the 
second probability test (1.1% in Canada and 1.8% in the United States). A similar proportion of 
respondents initially indicated a preference for the person with the higher risk in the probability 
choice question (11% in the United States and 13% in Canada). However, most of these 
respondents corrected their answers when asked the question a second time. Only 1.3% of each 
sample confirmed that they would prefer to be the person with the higher risk of death. 
Combining the responses to the test and choice questions, about 3% of each sample 
answered the initial probability test question incorrectly and indicated a preference for the person 
with the higher chance of dying in the probability choice question. These respondents were 
removed from subsequent analyses.  
In Table 5 we examine the acceptance of the risk-reducing product or action and the 
scenario presented in the questionnaire. Roughly 20% to 25% of the respondents did not believe 
the baseline risk figures that were presented to them. Most of these respondents thought that their 
own risks of death were lower than the questionnaire stated. Approximately one-third of the 
respondents in each sample had doubts about the effectiveness of the product or action, with a 
large fraction of these respondents stating that these doubts influenced their WTP for the product 
or action itself.  Resources for the Future  Alberini et al. 
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Some respondents worried about side effects of the product; others thought that the 
product would yield additional benefits. A larger proportion of Hamilton respondents were 
concerned about possible side effects and admitted thinking about other benefits of the product 
than people in the U.S. sample. In the U.S. study, respondents were asked about the kinds of 
additional benefits they had in mind. Their replies included additional benefits to themselves 
(40%), benefits to other people—such as family members—of their living longer (25%), and 
improved health for other people (26%). 
In Hamilton, 26% of the respondents noted that they did not consider whether they could 
afford the product or action when answering the payment question. In the United States, the 
fraction of the sample reporting such a behavior was even higher (37%). As discussed in 
Krupnick et al. (2002), these responses were common among people who were not willing to pay 
anything for the product. We conclude that most of these respondents had already ruled out the 
purchase of the product or action, making the price irrelevant to their decision. Finally, about 
14% of the respondents revealed that they had not understood that they would be required to 
make a payment every year for ten years in order to receive the product and secure its risk-
reducing benefits. 
V. Willingness to Pay Results 
A. Validity of WTP Responses 
Before we examine the impact of age and health on WTP, it is important to establish 
criteria that WTP responses must satisfy for consistency with economic theory. We use three 
such criteria. First, the percentage of respondents answering “yes” to the initial payment question 
must decline with the dollar amount presented to the respondents. Second, respondents should be 
willing to pay more for a larger risk reduction. Third, under the assumptions in section II, 
willingness to pay should be proportional to the size of the risk reduction.8  
To see whether the first criterion is met, we use only the responses to the initial payment 
question. Figures 2 and 3 show clearly that the first requirement is easily met in both studies: the 
percentage of “yes” responses clearly declines with the bid amounts used for the initial payment 
                                                 
8 Equation (4) implies that WTP equals the rate at which an individual is willing to trade wealth for risk (VSLj), 
multiplied by the size of the risk reduction. For small variations in Dj, VSLj should remain constant. Resources for the Future  Alberini et al. 
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questions. For the 5-in-1,000 risk reduction (wave 1), about 73% of the respondents are willing 
to pay the lowest bid amounts used (C$100 in the Hamilton study and $70 in the U.S. study). 
Smaller proportions are willing to pay the highest bid amounts (26% in Canada and 35% in the 
United States). A similar reaction to the 1-in-1,000 risk reduction (wave 2) is also found in both 
countries. The fraction of the sample willing to pay for the 1-in-1,000 risk reduction declines 
from 49% (for C$100) to 20% (C$1,100) in Canada, and from 44% (for $70) to 13% ($725) in 
the United States.  
Furthermore, the percentages of respondents willing to pay for the 1-in-1,000 risk 
reduction are smaller than those for the 5-in-1,000 risk reduction at all bid levels. We therefore 
expect that when a formal estimate of mean WTP is obtained, WTP for the two risk reductions 
will be found to be significantly different. 
B. External Scope Tests 
To test whether WTP increases in proportion to the size of the risk reduction, we utilize 
the responses to the initial payment questions as well as the subsequent round of followups, fit a 
formal statistical model of WTP, and use the latter to produce estimates of mean WTP for the 
specified risk reductions. 
A crucial decision is whether to use the open-ended responses that follow the first and 
second dichotomous choice questions. In both surveys, subjects answering no to both sets of 
dichotomous choice questions were asked whether they would pay anything at all for the 
product. As is often the case in contingent valuation surveys, a relatively high proportion of 
respondents in both samples indicated that they were not willing to pay anything for the risk 
reduction.9 However, in the analyses reported in this paper we elect not to use these responses or 
the open-ended WTP amounts reported by persons who answered yes to the initial and followup 
dichotomous choice question. Although positive WTP amounts reported on a continuous scale 
are easily accommodated within a maximum likelihood estimation framework, we were 
                                                 
9 In Canada, 19.5% and 36.8% of the respondents indicated that they were not willing to pay anything at all for the 
5-in-1,000 (wave 1) and 1-in-1,000 (wave 2) risk reductions, respectively. The corresponding U.S. figures are 22% 
and 37.7%.  Resources for the Future  Alberini et al. 
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dissatisfied with the performance of the models we devised to accommodate zero WTP 
responses.10  
For these reasons we use only the responses to the two rounds of dichotomous choice 
questions. Our statistical model is an interval-data model based on the Weibull distribution and is 
estimated using the method of maximum likelihood. The log likelihood function of the responses 
is: 
(7)     [ ] ∑ − =
i




i ) , ; ( ) , ; ( log log σ θ σ θ  
where F(•;θ,σ) is the cdf of the Weibull distribution with shape parameter θ and scale σ 
( ) ) / ( exp( 1 ) , ; (
θ σ σ θ y y F − − = ), and WTP
L and WTP
U are the lower and upper bounds of the 
interval around the respondent’s WTP amount. 
Estimates of median and mean annual WTP based on equation (7) without using 
covariates are reported in Table 6.11,12 We exclude from our models those respondents who failed 
both the initial probability test and the probability choice questions described above, whether or 
                                                 
10 We have attempted two such models. In the first model, responses are treated as if they came from a discrete 
mixture with two components. The first component is a degenerate distribution where all respondents hold a value 
of zero for the risk reduction, and the second component is a well-behaved random variable (a Weibull) that takes 
only positive, real values. Unfortunately, the estimation routine experienced convergence problems for all but the 
simplest specifications. The second model is an interval-continuous data version of the “spike” model described by 
Kristrom (1997). In this case, the estimation routine converged without problems, but we were concerned about the 
restriction implicitly imposed in this model that the coefficients be the same for zero-WTP respondents and for 
respondents who hold positive WTP amounts. This restriction appears to be violated in our data, at least for the U.S. 
study: Probit models to explain zero responses fail to identify any significant predictors of such responses among 
age, income, education, and variables measuring health status. The only variable that was consistently significant in 
explaining zero WTP was a dummy variable indicating that the respondent did not consider whether he could afford 
the payments. As discussed elsewhere (Krupnick et al. 2000), we believe that most of these respondents had already 
ruled out the purchase of the product, making the price irrelevant to their decision. 
 
11 All figures are expressed in U.S. dollars, based on a purchasing power parity for US$1.25 per C$1. 
12 Mean WTP is computed as  ) 1 ˆ / 1 ( ˆ + Γ ⋅ θ σ , and median WTP is 
θ σ
/ 1 ) 5 . 0 ln (− ⋅  where the hats denote 
estimates. To compute standard errors around mean WTP, we drew samples of 20,000 observations from a 
multivariate normal distribution centered on the estimated Weibull parameters with covariate matrix equal to the 
inverse of the information matrix of log likelihood (7). We used the values drawn from this distribution to compute 
20,000 estimates of mean WTP. The standard deviation of this vector of artificially generated mean WTP values is 
the standard error of the estimate of mean WTP shown in Table 7.  Resources for the Future  Alberini et al. 
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not they subsequently corrected their answers (FLAG 1=1). We also exclude respondents in the 
U.S. sample over the age of 80.13  
For both the Canadian and the U.S. samples, mean WTP and median WTP are 
significantly larger for a 5-in-1,000 risk reduction than for a 1-in-1,000 risk reduction, but 
neither mean WTP nor median WTP increases in proportion to the size of the risk reduction. 
Median WTP does, however, show more sensitivity to the size of the risk reduction than mean 
WTP: in both samples the ratio of median WTP for a 5-in-1,000 risk reduction to median WTP 
for a 1-in-1,000 risk reduction is larger than the corresponding ratio of mean WTPs.  
The corresponding estimates of the value of a statistical life are shown in Table 7. These 
are calculated using the mean annual WTP (from Table 6) and dividing it by the annual risk 
reduction implied by the product or action described to the respondent.14 Given the similarity of 
the WTP figures from the Canadian and U.S. studies, it is not surprising that the VSLs are also 
very similar.  
The VSL estimates for Canada range from $506,000 to $933,000, when computed using 
WTP for the 5-in-1,000 risk reduction, compared with $700,000 to $1.54 million for the United 
States. When based on WTP for the 1-in-1,000 risk reduction, the VSL estimates increase, 
exceeding $4 million. Because WTP is generally not proportional to the size of the risk change, 
VSL estimates are larger when calculated using WTP for the smaller risk change. Although the 
more generous VSL amounts for Canada appear in line with estimates used in policy assessments 
affecting elderly populations, they are well below the estimates used by EPA in its recent policy 
analyses. 
Returning to the issue of sensitivity to scope, when we distinguish respondents by the 
degree of confidence they have in their answers, median WTP does, indeed, increase in 
proportion to the size of the risk reduction. This is shown in Table 8. After each WTP question, 
we asked respondents to indicate the level of certainty they had in their responses on a scale from 
1 to 7. In Table 8, certainty levels of 6 and 7 are categorized as “more confident” and all other 
                                                 
13 We decided to exclude respondents older than 80 years because in our preliminary analyses of the relationship 
between WTP and age, we found that in the oldest age bracket (age 80 and older), this relationship appeared to be 
nonmonotonic and driven by a few responses implying relatively large WTP amounts. Since there were only 11 
subjects in this age group, we deemed it safer to exclude these respondents from our analysis.  
14 Assuming that the respondents spread the risk reduction evenly over the 10 years, this approach overcomes the 
difficulty of having to choose a discount rate for the 10 annual payments.  Resources for the Future  Alberini et al. 
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certainty levels as “less confident.” When attention is restricted to more confident respondents, 
the ratio between the median WTP amounts is 3.3 for Canada and 8.9 for the United States, with 
neither figure statistically different from 5. These results, however, should be interpreted with 
caution because of the large confidence intervals around the point estimates of the ratio between 
WTP for the two risk reductions. 
C. The Impact of Age and Health on WTP 
To examine the impact of age and health on WTP, we add covariates to the Weibull 
model. The life-cycle model presented in section II suggests that current wealth and a person’s 
future income stream should influence his WTP for a reduction in risk of death. So should 
covariates that may alter the individual’s estimate of his chances of surviving the next 10 years, 
(1-Dj). These include, in addition to a person’s own age and health, family health history, race, 
and gender. These same variables, of course, should influence estimates of future survival 
probabilities, so their net impact on WTP is uncertain. 
We present results of interval-data Weibull regressions of WTP in Table 9 for the 5-in-
1,000 risk reduction based on wave 1 for both the U.S. and the Canadian samples. The Weibull 
regressions assume that 
θ β
/ 1
0 ) exp( WTP x WTP
i = , where WTP0 is WTP when all covariates are 
set to zero, which is distributed as a Weibull with shape parameter θ and scale 1. A log 
transformation produces the equation  ε θ β ) / 1 ( log
1 + = x WTP , where 
0 logWTP = ε  follows the 
type I extreme value distribution.  
The first model presented in Table 9 examines the effects of age on WTP using a series 
of dummy variables to represent age groups 50 to 59, 60 to 69, and 70 and older. When these 
dummies are included on the right-hand side of the Weibull model, the coefficients of the 50–59 
and 60–69 age group dummies are indistinguishable from the coefficient of the 40–49 age 
bracket (captured by the intercept). The coefficient of the oldest age bracket, however, is 
significantly lower for the Canadian sample, at the 10% level. This remains true when other 
covariates are included in the regression. No age effects are found using the U.S. sample. 
Model 2 examines, in addition to age, the impacts of race, gender, income, and education 
on WTP. In the U.S. sample, income is measured as household income divided by number of 
persons in the household. Information about household size is not available for the Canadian 
sample. Instead, for the Canadian sample, the Weibull regression includes a dummy that takes on 
a value of one if the respondent’s household income is below the first quartile. In both samples 
higher income increases WTP, although this effect is statistically significant only in the U.S. Resources for the Future  Alberini et al. 
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sample. In the U.S. sample, blacks are willing to pay more for a 5-in-1,000 risk reduction than 
whites and Hispanics, possibly because they have higher baseline risks, whereas males are 
willing to pay less. Education does not have a statistically significant effect on WTP. 
Model 3 examines the impact of family health history, health insurance coverage, and 
hospital admissions on WTP. These variables are insignificant in both samples, with two 
exceptions. Having a family history of chronic heart or lung disease increases WTP by 26% in 
the Canadian sample, and by 37% in the U.S. sample. More strikingly, in the United States, 
respondents who have been admitted to the hospital for a heart or lung condition within the last 
year or who have been admitted to an emergency room for one of these conditions within the last 
five years are willing to pay 63% more to reduce their risk of death than persons who have not 
had such hospital visits.15 
In addition to recording hospital admissions, we measure respondents’ health status by a 
series of dummy variables that indicate whether a respondent has ever been diagnosed with 
cardiovascular disease, chronic lung disease, high blood pressure, or cancer.16 Because of 
correlations among these variables, we add the chronic health dummies one at a time to model 2 
and to model 3 of Table 9.17 These coefficients appear in Table 10. In the Canadian sample, none 
of the chronic health dummies are ever statistically significant. In the U.S. sample, the dummy 
variables for cancer and cardiovascular disease are never statistically significant; however, 
having blood pressure raises WTP by about one-third, even when family health history and 
hospitalization are controlled for. Having a chronic respiratory illness significantly raises WTP 
when the latter variables are omitted from the equation (model 2), but not when they are added 
(model 3). We conclude that having a chronic heart or lung condition certainly does not appear 
to reduce WTP for mortality risk reductions and may even increase WTP. 
                                                 
15 We note that the effects of age, race, gender, income, and family health history are, in general, robust to the 
inclusion of variables indicating whether the respondent questioned baseline risk figures or the assumptions of the 
WTP scenario. (The results of adding the debriefing variables to Model 3 are reported in Table A.1.) When 
significant, the coefficients on the debriefing variables are of the correct sign. 
16 We have chosen to focus on indicators of chronic illness rather than indicators of functional limitation, as 
measured by the indices from SF-36. The latter are often correlated with the former; however, it is the former that 
are used more often in epidemiological studies. 
17 We also tried interacting each health dummy with the emergency room–hospitalization variable, but these terms 
were never significant. Resources for the Future  Alberini et al. 
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D. Conclusions and Implications for Policy  
In this paper we have used contingent valuation to examine the effects of current age and 
health status on respondents’ WTP for a product that would reduce their risk of death over the 
next 10 years. Economic theory is ambiguous about the impact of these variables on WTP to 
reduce risk of death. In general, WTP should be higher the lower an individual’s chances of 
surviving the current period. It should also be higher the greater the present discounted value of 
lifetime utility conditional on surviving the current period. In a comparative static sense, being 
older and having a chronic heart or lung condition both reduce an individual’s chances of 
surviving the current period and, for this reason, tend to raise WTP. Older individuals and 
persons with chronic diseases, however, have fewer life years to look forward to, assuming they 
survive the current period, and this should lower their WTP to reduce current risk of death.  
Our empirical results suggest that with regard to health status, the former effect balances 
out the latter and may even dominate it: persons with chronic heart and lung disease are willing 
to pay at least as much to reduce their risk of dying as persons who do not have these diseases. In 
our U.S. sample, WTP is significantly greater (holding age, gender, and income constant) for 
persons who have been hospitalized for a chronic heart or lung condition within the last year and 
for persons who have high blood pressure. There are no statistically significant differences 
between the two groups in Canada. 
As regards age, respondents in our Canadian sample who were 70 years of age or older 
were willing to pay about one-third less than their younger counterparts to reduce their risk of 
dying over the next 10 years. There was, however, no statistically significant impact of age on 
WTP in the U.S. sample. 
Our results thus support current practice with regard to treatment of age and health status 
in both the United States and Canada. EPA currently uses a central VSL estimate, based 
primarily on labor market studies, equal to approximately $6 million (1999 US$) for all ages. In 
contrast, Health Canada employs age-adjusted VSL estimates in its economic assessments, 
applying a VSL of C$5 million (or US$4 million) to exposed populations under 65 years of age 
and using an adjustment factor of 0.75 for populations 65 years and older.18 Neither agency 
currently makes adjustments based on health status. 
                                                 
18 These adjustments are based on Jones-Lee et al. (1985). 
 Resources for the Future  Alberini et al. 
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These results stand in sharp contrast to the way in which age and health status are treated 
in evaluating medical interventions. We believe the comparison is relevant, since it is sometimes 
suggested that a similar approach be used in benefit-cost analyses of health and safety 
regulations (U.S. Food and Drug Administration 1999). The standard approach in the medical 
literature is to measure life-saving benefits in terms of Quality Adjusted Life Years Saved 
(QALYs). This assumes that the value of lives saved is strictly proportional to remaining life 
expectancy, and that the value of saving a life-year is less for a person with a chronic disease, 
such as chronic bronchitis, than for a healthy person, with the exact equivalence determined by 
QALY weights. Our results do not support either of these assumptions. There is no evidence that 
the VSL should be equally apportioned over remaining life expectancy, or that the VSL is 
systematically lower for persons with chronic illness. 
 Resources for the Future  Alberini et al. 
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Figure  3. 
Percentage of "Yes" Responses by Bid Value: U.S. Study 




























Followup question (if 
“yes”) 
Followup question (if 
“no”) 
I 100  225  50 
II 225  750  100 
III 750  1100  225 
IV 1100  1500  750 
 
Note: 
* Similar bid values were used in the U.S. survey after conversion to U.S. dollars using purchasing power 




Table 2.  
Comparison across Canadian and U.S. Mortality Risk Studies:  
Characteristics of Respondents 
 
Sample average or percentage of sample   
Characteristic  Canada United  States 
Age  54.2 years  54.4 years 
Male 48%  47% 
Racial and ethnic composition 
African American  —  11%  
Hispanic  —  8%  
White 100%    82% 




African American  —  174 
No African American  
Or persons older than 75 
—  147 
Household characteristics 
Annual household income (US $) 
        Mean 







Years of schooling  13.7  13.0  
Married   —  72% 
Household size  —  2.6 
Number of adults in the household  —  2.2 
Percent urban/suburban in county 
of residence  




Comparison of Respondent Health Status  
 
Across the Canada and U.S. Studies 
 
Sample mean or percent    
Health Condition  Canada United  States 
Has asthma  10 % 







Has angina pectoris  8 % 
Has had a myocardial infarction (heart attack)  8 % 







Has had a stroke  --  4 % 
Has been diagnosed with cancer  3 %   11 % 
ER visit in last 5 years or hospitalization in 
last year for ongoing heart or lung problems 
12% 12% 
Has family history of cancer  49%  52% 
Has family history of chronic illness 
(excluding cancer) 
79% 50% 
Has no medical insurance
* 31%  6% 
General health score from SF-36  70  67 
Physical functioning score from SF-36  81  78 
Vitality score from SF-36  63  59 
Role-emotional score from SF-36  81  87 
Mental health score from SF-36  76  77 
Rates own health as good or excellent, 
relative to others of the same age 
57 %  53 % 
* chronic  bronchitis 
*    “No medical insurance” is defined in Canadian sample as “no supplemental insurance coverage.” Resources for the Future  Alberini et al. 
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Table 4.  
Comparison across Canadian and U.S. Mortality Risk Studies: Probability 
Comprehension 
Percentage of the sample   
Canada United  States 
Probability test questions answered incorrectly  
1st probability test question   11.6  12.2 
2nd probability test question (FLAG 4)  1.1  1.8 
Indicates preference for individual with higher risk of death in 
1st probability choice question  13.0  10.8 
Followup confirmation question (FLAG 5)  1.3  1.3 
Other indicators of probability comprehension 
Fails both probability test and choice 
questions (FLAG 1) 
2.6 3.7 
Claims to understand probability poorly 
(FLAG 6) 
7.0 16.2 Resources for the Future  Alberini et al. 
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Table 5. Comparison across Canada and U.S. Studies 
Acceptance of the Product and Scenario 
Percentage of the sample 
 
Canada United  States 
Did not believe the risk figures (FLAG 7)  19.7  24.5 
Thought own risks were higher  15.9*  20.5* 
Thought own risks were lower  84.1*  79.5* 
Doubts effectiveness of the product or action (FLAG 8)  30.6  33.5 
Doubts about effectiveness influenced WTP (FLAG 9)  19.7  21.1 
Thought about possible side effects of the product 
(FLAG10) 
25.0 15.4 
Thought of other benefits of the product (FLAG 11)  48.7  36.6 
Other benefits to self  —  39.7** 
Benefits to other people of living longer  —  25.2** 
Improved health for other people  —  25.7** 
Did not consider whether he could afford the product or 
action (FLAG 15) 
26.0 37.4 
Did not understand the timing of the payments (FLAG 16)  13.0  14.0 
* Percentage of respondents who did not believe the risk figures.  
** Percentage of respondents who thought of other benefits of the product. Resources for the Future  Alberini et al. 
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Table 6.  
Mean and Median WTP for Reduced Mortality Risk (U.S. dollars*) 
Canada United  States   
Median WTP  Mean WTP  Median WTP  Mean WTP 




























Are the WTP figures for risk reductions of different sizes… 
Significantly different?  Yes Yes  Yes Yes 
Wald Test  23.74  2.65  56.10 6.32 
 p-value  <0.0001  0.10  <0.0001 0.01 
Proportional to the size of 









Wald Test  19.0  32.0  7.3 18.7 
p-value  < 0.0001  < 0.0001  0.007  < 0.0001 
Notes: Standard errors in parentheses. Estimates based on cleaned data (respondents with FLAG 1=1 deleted). U.S. 
sample excludes people older than 80 years of age. 
* In U.S. dollars, using purchasing power parity of C$1.25 per US$1. 
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Table 7.  
Implied Estimates of the Value of a Statistical Life (US$) 
 
Canada United  States   










5 in 1,000  506,000  933,000  700,000  1,540,000 
1 in 1,000  1,312,000  3,704,000  1,110,000  4,830,000 
Note: VSLs are computed using on annual risk changes—that is, 5 in 10,000 and 1 in 10,000. 
 Resources for the Future  Alberini et al. 
 
Table 8.  
The Effect of Confidence on Median WTP for Reductions to Mortality Risk (US$) 
 
Canada median WTP  U.S. median WTP   
Magnitude of risk 
reduction 
More confident  Less confident More  confident  Less 
confident 




























Are the WTP figures for risk reductions of different sizes… 
Significantly different?  Yes  Yes  Yes  Yes 
 Wald Test  25.95  9.51  18.04  22.48 
 p-value  <0.0001  0.002  <0.0001  <0.0001 
Proportional to the size of 









 Wald Test  1.99  11.8  2.04  31.21 
 p-value  0.15  0.0006  0.15  <0.0001 
 
Note: Standard errors in parentheses. Estimates based on cleaned data (respondents with FLAG 1=1 deleted; 
respondents older than 80 excluded). Resources for the Future  Alberini et al. 
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Table 9.  
Weibull Interval-Data Regression Results for 5-in-1,000 Risk Reduction (Wave 1) 
 
Canada United  States   
Variable  Model 
1 
Model 2  Model 3  Model 1  Model 2  Model 3 




























































Bottom 25% of distribution of 






— —  — 















Family history of chronic 
illness (excluding cancer) 
— —  0.26* 
(0.16) 
— —  0.37* 
(0.22) 
Family history of cancer  —  —  -0.06 
(0.13) 
— —  0.02 
(0.17) 
ER visit in last five years or 
hospitalization in last year 
— —  -0.07 
(0.19) 
— —  0.63** 
(0.28) 
No insurance  —  —  -0.03 
(0.15) 
— —  0.29 
(0.28) 












Sample  size  616  605 605 551 474  474 
Notes: Standard errors in parentheses. ** indicates significance at the 5% level; * indicates significance at the 10% 
level. FLAG 1=1 deleted. U.S. sample excludes people older than 80 years of age. 
 Resources for the Future  Alberini et al. 
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Table 10. Effect of Adding Health Variables One at a Time to Previous Models 
 
Canada United  States   
Characteristic  Model 2 +  Model 3 +  Model 2 +  Model 3 +
CARDIO
































Note: ** indicates significance at the 5% level; * indicates significance at the 10% level. FLAG1=1 
deleted. U.S. sample only includes people of ages no greater than 80 years.  
≅ Definition of CARDIO: respondent has one or more of the following: angina pectoris, coronary disease, 
other heart diseases, and/or has had a myocardial infarction. Resources for the Future  Alberini et al. 
34 
 
Table A1. The Effect of Acceptance of the Product and Scenario on 
Weibull Interval-Data Regression Results for 5 in 1,000 Risk Reduction (Wave 1) 
(Standard Errors in Parentheses)  
Variable Canada  United  States 




















Black --  0.79** 
(0.36) 
Bottom 25% of distribution of income 




Income per Person  --  0.000017** 
(6.62x10
-6) 














ER visit in last five years or 















Does not believe the product would 















Did not consider if could afford 





Did not understand timing of 









Sample size  605  474 
Note:  ** indicates significance at the 5% level; *  indicates significance at the 10% level. FLAG1=1 
deleted. U.S. sample only includes people of ages no greater than 80 years.   